Table of Content

1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary research respondent, By Region
2.5. Assumption & Limitation

3. Executive Summary

4. Global Antidiabetics market Industry Insights
4.1. DROC Analysis
4.1.1. Growth Drivers
4.1.2. Restraint
4.1.3. Opportunities
4.1.4. Challenges
4.2. Technological Landscape/Recent Development
4.3. Regulatory Framework
4.4. Company Market Share Analysis, 2019
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry
4.6. Impact of COVID 19

5. Global Antidiabetics market Overview
5.1. Market Size & Forecast by Value, 2016-2026
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Product
5.2.1.1. Insulin
5.2.1.1.1. Rapid acting analog
5.2.1.1.2. Long acting analog
5.2.1.1.3. Short acting analog
5.2.1.1.4. Intermediate acting insulin
5.2.1.1.5. Others
5.2.1.2. Drug class
5.2.1.2.1. Alpha glucosidase inhibitors
5.2.1.2.2. Biguanides
5.2.1.2.3. Sulphonylureas
5.2.1.2.4. GLP-1 (Glucagon like peptide) agonists
5.2.1.2.5. others
5.2.2. By Patient Population
5.2.2.1. Pediatric
5.2.2.2. Adult
5.2.2.3. Geriatric
5.2.3. By Route of Administration
5.2.3.1. Insulin syringe/ Insulin pen
5.2.3.2. Insulin pump
5.2.3.3. Intravenous infusion
5.2.3.4. Oral
5.2.3.5. Others
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. Asia Pacific
5.2.4.4. Latin America
5.2.4.5. Middle East & Africa

6. North America Antidiabetics Market
6.1. Market Size & Forecast by Value, 2016-2026
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Patient Population
6.2.3. By Route of Administration
6.2.4. By Country
6.2.4.1. United States
6.2.4.2. Canada

7. Europe Antidiabetics market
7.1. Market Size & Forecast by Value, 2016-2026
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Patient Population
7.2.3. By Route of Administration
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. United Kingdom
7.2.4.3. France
7.2.4.4. Italy
7.2.4.5. Spain
7.2.4.6. Rest of Europe

8. Asia Pacific Antidiabetics Market
8.1. Market Size & Forecast by Value, 2016-2026
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Patient Population
8.2.3. By Route of Administration
8.2.4. By Country
8.2.4.1. India
8.2.4.2. China
8.2.4.3. Japan
8.2.4.4. South Korea
8.2.4.5. Rest of Asia Pacific

9. Latin America Antidiabetics Market
9.1. Market Size & Forecast by Value, 2016-2026
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1.1. By Product
9.2.1.2. By Patient Population
9.2.1.3. By Route of Administration
9.2.1.4. By Country
9.2.1.4.1. Brazil
9.2.1.4.2. Mexico
9.2.1.4.3. Rest of Latin America

10. Middle East & Africa Antidiabetics Market
10.1. Market Size & Forecast by Value, 2016-2026
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1.1. By Product
10.2.1.2. By Patient Population
10.2.1.3. By Route of Administration
10.2.1.4. By Country
10.2.1.4.1. Saudi Arabia
10.2.1.4.2. UAE
10.2.1.4.3. South Africa
10.2.1.4.4. Rest of Middle East & Africa

11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
11.1. Sanofi Aventis
11.2. Takeda Pharmaceuticals
11.3. Eli Lilly
11.4. Oramed Pharmaceuticals Inc.
11.5. Merck & Co. Inc.
11.6. Novo Nordisk
11.7. Bristol-Myers Squibb
11.8. Halozyme Therapeutics
11.9. Pfizer
11.10. Novartis AG
11.11. Takeda Pharmaceutical
11.12. Johnson & Johnson
11.13. Other Prominent Players
* Financial details in case of unlisted companies will be available as per data availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.